Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults aged 18 years and older
Positive COVID-19 test confirmed by RT-PCR, antibody test, or antigen test at least 3 months prior to randomization, OR presumed COVID-19 evaluated by the site investigator (no positive test required) with an acute illness occurring after October 15, 2019 and at least 3 months prior to randomization.
Persistent symptoms ≥12 weeks after onset of acute COVID-19 AND symptoms lasting at least 2 months. The onset date is defined as the earliest of: date of first positive test, date of first symptoms
Post-COVID Functional Status Scale score ≥2.
Persistent dyspnea ≥2/4 on the mMRC scale at least 12 weeks post-infection.
Persistent COVID-19-related symptoms at the time of randomization.
If taking medications for fatigue or cognition (e.g., sildenafil, modafinil, armodafinil, guanfacine, N-acetylcysteine, stimulants for ADHD), these must have been initiated and stable for ≥4 weeks prior to randomization. Participants are asked not to stop or alter these medications during the study if possible.
Able and willing to provide written informed consent.
Able to read and understand French.
You may not be if
Prior diagnosis of myalgic encephalomyelitis (ME) or fibromyalgia
Being on sick leave or disability at the time of the original acute COVID-19 infection.
Pregnancy or breastfeeding.
Myocardial infarction within the last 12 weeks.
Use of anticoagulant therapy.
Glaucoma.
Emphysema requiring home oxygen.
Cardiac conduction abnormalities.
Known hypersensitivity to bupivacaine.
Previous stellate ganglion block (SGB) procedure.
Any condition that, in the judgment of the medical investigator, makes the patient not a candidate for the proposed treatment.
Clareo Health | Stellate Ganglion Block for Long COVID Symptoms: A Randomized Controlled Trial
